Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | RRM1 | P23921 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25615703 | 0.83 | EPHX1 (0.42) | EPHX1CASP2ZDHHC20ZDHHC2MGLL | |
| SCHEMBL14996213 | 0.82 | KDM1A (0.40) | EPHX1CASP2ZDHHC20ZDHHC2MGLL | |
| SCHEMBL11484382 | 0.81 | EPHX1 (0.42) | EPHX1CASP2ZDHHC20ZDHHC2MGLL | |
| SCHEMBL13631010 | 0.81 | EPHX1 (0.42) | EPHX1CASP2ZDHHC20ZDHHC2MGLL | |
| SCHEMBL22943391 | 0.81 | GRIN2D (0.38) | EPHX1MGLLDPP7RRM1 | |
| SCHEMBL22965147 | 0.80 | DNM1 (0.45) | EPHX1 | |
| SCHEMBL21927806 | 0.77 | EPHX1 (0.34) | EPHX1MGLLNAAA | |
| SCHEMBL12344051 | 0.77 | EPHX1 (0.43) | EPHX1CASP2ZDHHC20ZDHHC2MGLL | |
| SCHEMBL13488627 | 0.77 | KDM1A (0.41) | EPHX1MGLL | |
| SCHEMBL21473536 | 0.75 | DNM1 (0.42) | EPHX1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | EPHX1 886/4885CASP2 1559/4885ZDHHC20 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.